Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02264639 · ClinicalTrials.gov registry record · Phase 1
A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH
A Phase 1 study, sponsored by Apellis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 9
- Enrollment target
NCT02264639 is a Phase 1 study that has completed, run by Apellis Pharmaceuticals. The registered enrollment target is 9 participants.
The verdict
NCT02264639, a Phase 1 study, has completed, sponsored by Apellis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 9 participants
- Enrollment target
Study Summary
This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.
Interventions
- DRUG Pegcetacoplan
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 9 participants |
| Start Date | 2015-02-23 |
| Est. Completion | 2018-10-22 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02264639
The ClinicalTrials.gov registry entry for NCT02264639 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 9 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Apellis Pharmaceuticals, which has 21 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Pegcetacoplan is the first listed.
NCT02264639 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02264639 about?
NCT02264639 is a clinical study titled "A Phase I Study to Assess the Safety of Pegcetacoplan (APL-2) as an Add-On to Standard of Care in Subjects With PNH". This study will be the initial exploration of pegcetacoplan in patients with PNH. The assessments of the safety, tolerability, PK, and PD following administration of single and multiples doses of pegcetacoplan will guide decisions to further develop the drug.
What is the current status of trial NCT02264639?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 9 participants. The study started on 2015-02-23. Estimated completion is 2018-10-22.
What interventions are being tested in trial NCT02264639?
The interventions under investigation include: Pegcetacoplan (DRUG).
Who is sponsoring clinical trial NCT02264639?
This trial is sponsored by Apellis Pharmaceuticals, which has 21 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.